Gsa Capital Partners LLP Larimar Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 107,408 shares of LRMR stock, worth $854,967. This represents 0.05% of its overall portfolio holdings.
Number of Shares
107,408
Previous 51,424
108.87%
Holding current value
$854,967
Previous $373,000
88.74%
% of portfolio
0.05%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding LRMR
# of Institutions
126Shares Held
67.1MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$169 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$48.1 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$44.3 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$33.8 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$33.2 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $344M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...